Liza Villaruz, MD of University of Pittsburgh Medical Center discusses the impact of atezolizumab on clinical practice and future clinical research at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract TPS9105: Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy
Advertisement